Vonbrunn, Eva
Büttner-Herold, Maike
Amann, Kerstin
Daniel, Christoph http://orcid.org/0000-0002-6803-4755
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (387509280, 387509280, 387509280)
Friedrich-Alexander-Universität Erlangen-Nürnberg
Article History
Accepted: 9 November 2022
First Online: 13 December 2022
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL. This study was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), project number 387509280, SFB 1350 TP C2.
: Maike Büttner-Herold reports lecture fees from Alexion Pharma Germany GmbH, Novartis Pharma GmbH, Sanofi and Pfizer Pharma GmbH and Kerstin Amann reports consulting fees from Novartis Pharma GmbH and Otsuka Pharmaceutical Co. and lecture fees from Alexion Pharma Germany GmbH, Shire Pharmaceuticals, AstraZeneca, Novartis Pharma GmbH. All other authors report no potential conflicts of interest or financial disclosures that are pertinent to the article.
: Not applicable.
: Not applicable.
: Not applicable.
: This article is a review article that does not include original data.
: Not applicable.
: EV and CD provided general information on the complement system, clinical interpretation, created figures and drafted and reviewed all versions of the manuscript. MB-H created figures and drafted and reviewed all versions of the manuscript. KA drafted and reviewed all versions of the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.